deltatrials
Completed PHASE3 NCT00631371

Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects

Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma

Sponsor: Pfizer

Conditions Renal Cell Carcinoma
Interventions Bevacizumab Interferon-Alfa 9MU Temsirolimus
Updated 7 times since 2017 Last updated: Mar 25, 2016 Started: Apr 30, 2008 Primary completion: Apr 30, 2012 Completion: Apr 30, 2015

This PHASE3 trial investigates Renal Cell Carcinoma and is currently completed. Pfizer leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Apr 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia, Ahmedabad, India, Antwerp, Belgium, Bangalore, India, Banská Bystrica, Slovakia, Barcelona, Spain, Bari, Italy, Barretos, Brazil, Belgrade, Serbia, Berlin, Germany and 116 more location s